RetinaLyze System A/S (Ltd.) is launching a new artificial intelligence (AI)-based tool for a stable and consistent method of tracking glaucoma: the Advanced Glaucoma Progression AI featuring the Glaucoma Index of Progression (GIP).
First, give me a rundown on RetinaLyze.
Based in Denmark, the software company is developing AI and telemedicine solutions for the healthcare industry (hospitals and clinics)—with a specific focus on optometry.
- Its areas of focus: diabetic retinopathy (DR); age-related macular degeneration (AMD), and glaucoma
About this software: Originally debuting in 2018, this eye-screening technology (a web application) is designed to assist eye care professionals (ECPs) with screening for signs of pathology via automated AI analyzing fundus images and optical coherence tomography (OCT) scans.
And how is it intended to benefit clinicians?
- Optometrists: By incorporating the software into their eye health services as part of branding, compliance, and operational efficiency
- Hospitals / clinics: By increased efficiency via offloading routine tasks of ECPs to nurses, and increased screening quality by earlier referrals
Note: The software can be utilized as either a clinical decision support system (CDSS) or in tandem with a telemedicine module.
Is it clinically validated?
RetinaLyze has received a CE mark from the European Union (EU) and is noted as being a “clinically validated system” that uses high encryption levels to store all clinical data, images, and communication.
- See here for info on how to get started with eye screening in your clinical practice (if you’re a practitioner in the EU, that is).
Can I get a visual of this?
Check out this thorough walkthrough of the software, from how to upload images/scans to setting up consultations “saving time with AI for OCT.”
https://youtu.be/Kr6oowjlaMw
Okay, now talk about this new tool.
The Advanced Glaucoma Progression AI featuring the Glaucoma Index of Progression (GIP) is, essentially, designed to monitor glaucoma changes and assist clinicians in detecting early subtle changes.
Why this advancement is important: RetinaLyze noted that such a tool can provide crucial insights for ECPs.
“It’s essential to keep in mind that ‘normality’ in medical terms is statistically defined, meaning a patient’s condition could deteriorate even if their metrics remain within a so-called normal range,” the company stated.
What kind of features are included?
A major component: Simultaneously comparing changes between eyes.
- What this does: Enables ECPs to examine GIP indices plus estimated areas of optic cup and rim sectors
- The result: A more “comprehensive overview” that gives clinicians a better idea of disease progression/regression that’s affecting the optic nerve and surrounding structures
And what sets GIP apart from other glaucoma trackers?
Per RetinaLyze, it’s the tool’s reduced reliance on deep learning algorithms—“making it particularly valuable for longitudinal studies where consistency is key.”
Can I get a walkthrough on this, too?
Check out 03:18 in the above video for how this tool works within the software.
Nice! So is this cleared for use in the U.S.?
Not yet … and that goes for North America (excluding Mexico).
The software is currently available in Mexico and the EU.
Stay tuned in the near future though!
And where can I test out software + digital tool?
Consider signing up for a free 30-day trial (provided you’re not a practicing ECP in North America …)